『The Business Of Neurotech』のカバーアート

The Business Of Neurotech

The Business Of Neurotech

著者： Adam Fraser
無料で聴く

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

From breakthrough devices to the bottom line. The Business of Neurotech is the premier podcast dedicated to the commercial trends, investment strategies, and innovative business models shaping the neuroscience economy. Hosted by Adam Fraser, this series moves beyond the lab to explore how groundbreaking research in neuromodulation, BCI, and medical devices is transformed into viable, scalable enterprises. +2 Each episode features candid, fireside-chat interviews with the ecosystem's most influential voices—from founders and CEOs to venture capitalists and strategic leaders. We dive into the "how" and "why" behind the headlines, discussing market maturity, regulatory hurdles, and the go-to-market strategies required to bring neurotechnology to the global stage. +3 Whether you are an investor conducting due diligence, a researcher exploring commercial applications, or an entrepreneur building the next generation of brain-tech, this show provides the strategic insights you need to navigate the future of the sector.

© 2026 Copyright 2026 - The Business of Neurotech
エピソード
  • Michael Brotherton Talks Neurotech Market Dynamics and Neurotech Investing

    Michael Brotherton Talks Neurotech Market Dynamics and Neurotech Investing
    2026/04/22

    What does it really take to turn neurotechnology into a scalable business? In this episode of The Business of Neurotech, host Adam Fraser sits down with Michael Brotherton, co-founder and managing partner at Dragonfly 44, to explore the capital, strategy, and market forces shaping the sector. Michael talks about his journey from science into investment banking and how this ultimately led him to establish a business specialising in neuroscience and neurotechnology. He then delves into his definition of neuroscience and neurotech across devices, diagnostics, therapeutics, BCI, and digital tools. Adam and Michael also dig into the surge of investor interest in brain-computer interfaces, the growing overlap between neurotech, biomarkers, and AI, and why clinician networks and community-driven investing could become a real edge as the market matures. Tune in for a look at where neurotech is heading and what it may take to build lasting companies in the space with Michael Brotherton!


    Key Points From This Episode:

    • [00:58] Background about Michael and what led him to focus on neurotech.
    • [05:11] What type of expertise is needed to work in the neurotech space.
    • [07:21] Learn what neurotech is and what makes it stand out from other sectors.
    • [11:03] Find out why defining the size and scope of the neurotech market is still difficult.
    • [13:30] Explore what is driving such strong investor interest in brain-computer interfaces.
    • [15:12] Michael’s take on the most compelling neurotech subsectors today.
    • [17:02] Discover how Dragonfly 44 approaches servicing the neurotech market.
    • [19:10] What makes neurotech corporate finance different from medtech.
    • [21:37] Hear why building a venture fund was always part of Michael’s long-term vision.
    • [22:50] Unpack how AI could reshape investing, capital raising, and networking.
    • [29:04] How AI may lower startup capital requirements and open up more opportunities.
    • [30:21] Understand how Michael is thinking about his funding and networking efforts.
    • [34:16] Final comments and how to connect with Michael to learn more about his work.


    Links Mentioned in Today’s Episode:

    Michael Brotherton on LinkedIn

    Dragonfly 44 Capital

    D44 Ventures

    Neuroscience News

    Adam Fraser on LinkedIn

    Omniscient Neurotechnology
    続きを読む 一部表示
    36 分
まだレビューはありません